- Home
- / Verve Therapeutics
Verve Therapeutics
Stock Price
$5
2024-10-04
Market Capitalization
$423.1 M
2024-10-04
Verve Therapeutics Summary
Company Summary
- Overview
- Verve Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease. It develops medicines to edit the genome of adults that mimic naturally occurring gene variants to lower LDL cholesterol and triglyceride levels. Its products can be used for the treatment of coronary artery and cardiovascular diseases.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- Cambridge, MA, US | view all locations
- Website
- https://www.vervetx.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
J. Keith Joung, Co-Founder
Anthony Philippakis, Co-Founder, Board Member
Sekar Kathiresan, Co-Founder, Chief Executive Officer and Board Member
Verve Therapeutics Financials
Summary Financials
- Net income (Q2, 2024)
- ($49.8M)
- Cash (Q2, 2024)
- $141.5M
- EBIT (Q2, 2024)
- ($58.8M)
- Enterprise value
- $389.7M